Giannelos, Nikolaos http://orcid.org/0000-0001-9130-4744
Francq, Bernard http://orcid.org/0000-0002-6183-387X
Curran, Desmond http://orcid.org/0000-0002-7423-0111
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Accepted: 3 March 2024
First Online: 25 April 2024
Declarations
:
: GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO-000509) and was involved in all stages of the study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took charge of all costs associated with the development and publication of this manuscript.
: Nikolaos Giannelos, Bernard Francq, and Desmond Curran are employed by and hold shares in GSK. The authors declare no other financial and non-financial relationships and activities.
: Not applicable.
: Not applicable.
: Not applicable.
: The authors confirm that the data supporting the findings of this study are available within the article and its supplementary information.
: Not applicable.
: Shingrix is a trademark owned by or licensed to GSK. Zostavax is a trademark of Merck Sharp & Dohme Corp. AS01 is a trademark owned by or licensed to GSK.